Titan Pharmaceuticals, Inc. (TTNP) - חוב לטווח ארוך להון

The price trajectory of Titan Pharmaceuticals (TTNP) reflects the dynamics of the biopharmaceutical developer of the ProNeura system for CNS disorder therapy. Titan Pharmaceuticals is currently revising its business model and seeking new markets for implant sales, while the metric stands at 0.00. However, capital shortages, legal disputes, and weak demand for current solutions create significant barriers to the company's technological development.

This metric measures the proportion of long-term liabilities relative to equity, determining the issuer's level of financial autonomy. The calculation algorithm allows for the exclusion of short-term liabilities, focusing attention on the strategic debt load. By analyzing the long-term financial dependency ratio, an investor assesses the stability of the financing structure. For Titan Pharmaceuticals (TTNP), such a metric confirms a conservative approach to capital. This supports the stable profile of the company developing ProNeura technology.